CAMBRIDGE, Mass., Jan. 6, 2023
/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC)
today announced the appointment of John
Tsai, M.D., to its board of directors. Dr. Tsai, who was
President, Global Drug Development and Chief Medical Officer at
Novartis AG from 2018 to 2022, brings more than 20 years of drug
development and medical affairs experience in global pharmaceutical
companies to Blueprint Medicines.
"John's broad and deep experience in managing large pipelines
and diverse portfolios for global pharmaceutical companies will
make him a valuable Board member as we progress multiple
best-in-class clinical development programs in broad, established
therapeutic areas," said Kate
Haviland, Chief Executive Officer. "We very much look
forward to the perspective John will bring as we continue to
advance innovative precision medicine therapeutics that transform
the lives of patients with genomically defined diseases."
"Blueprint Medicines' success to date is impressive and the
company has a clear, exciting path to achieve its 2027 vision,"
said Dr. Tsai. "I look forward to leveraging my experience and
contributing to the wealth of knowledge within Blueprint as we work
to deliver more transformational medicines and impact more
patients' lives."
In addition, the company announced that George D. Demetri, M.D., FASCO, has retired from
the Board of Directors and will be joining its Scientific Advisory
Board. Dr. Demetri had served as a member of Blueprint's board of
directors since December 2014.
"George has been an integral member of our Board since the early
days of Blueprint and helped to guide the company through
significant milestones, including our initial public offering,
first clinical programs and several regulatory approvals," said Ms.
Haviland. "We are grateful for his leadership during the company's
most formative stages and that he will continue to support the
company's next phases as part of our Scientific Advisory
Board."
Dr. Tsai joins the Board of Blueprint Medicines with more than
20 years of experience in bringing innovative therapies to market
across geographies and therapeutic areas. Most recently, as
President, Global Drug Development and Chief Medical Officer at
Novartis AG, Dr. Tsai led the company's development portfolio
spanning 160 new projects and 500 clinical trials as well as the
team that secured global approvals for 15 new medicines including
treatments using gene therapy, cell therapies, and new advanced
platforms. Prior to joining Novartis in 2018, Dr. Tsai served as
Chief Medical Officer and Senior Vice President of Global Medical
Affairs at Amgen Inc. and spent 11 years at Bristol-Myers Squibb
Company. During his tenure at Bristol-Myers Squibb, Dr. Tsai held
positions of increasing responsibility within the Medical and Drug
Development organizations, including Head of Late Phase Development
and Oncology Development Leader, Head of Worldwide Medical Affairs,
Chief Medical Officer Europe, Head of U.S. Medical, and
Vice-President, Cardiovascular and Metabolics Disease Area. Earlier
in his career, Dr. Tsai held drug development roles at Pfizer Inc.
and manufacturing roles at General Electric Company. Dr. Tsai
received a B.S.E.E. in Electrical Engineering from Washington University in St. Louis and an M.D. from University of Louisville School of Medicine.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that
invents life-changing therapies for people with cancer and blood
disorders. Applying an approach that is both precise and agile, we
create medicines that selectively target genetic drivers, with the
goal of staying one step ahead across stages of disease. Since
2011, we have leveraged our research platform, including expertise
in molecular targeting and world-class drug design capabilities,
to rapidly and reproducibly translate science into a broad pipeline
of precision therapies. Today, we are delivering approved medicines
directly to patients in the United
States and Europe, and we
are globally advancing multiple programs for systemic mastocytosis,
lung cancer and other genomically defined cancers, and cancer
immunotherapy. For more information, visit
www.BlueprintMedicines.com and follow us on Twitter
(@BlueprintMeds) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding Blueprint Medicines' strategy, goals and anticipated
milestones, business plans and focus. The words "aim," "may,"
"will," "could," "would," "should," "expect," "plan," "anticipate,"
"intend," "believe," "estimate," "predict," "project," "potential,"
"continue," "target" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this report are based on management's
current expectations and beliefs and are subject to a number of
risks, uncertainties and important factors that may cause actual
events or results to differ materially from those expressed or
implied by any forward-looking statements contained in this report,
including, without limitation, risks and uncertainties related to
the impact of the COVID-19 pandemic to Blueprint Medicines'
business, operations, strategy, goals and anticipated milestones,
including Blueprint Medicines' ongoing and planned research and
discovery activities, ability to conduct ongoing and planned
clinical trials, clinical supply of current or future drug
candidates, commercial supply of current or future approved
products, and launching, marketing and selling current or future
approved products; Blueprint Medicines' ability and plans in
continuing to establish and expand a commercial infrastructure, and
successfully launching, marketing and selling current or future
approved products; Blueprint Medicines' ability to successfully
expand the approved indications for AYVAKIT/AYVAKYT and GAVRETO or
obtain marketing approval for AYVAKIT/AYVAKYT in additional
geographies in the future; the delay of any current or planned
clinical trials or the development of Blueprint Medicines' current
or future drug candidates; Blueprint Medicines' advancement of
multiple early-stage efforts; Blueprint Medicines' ability to
successfully demonstrate the safety and efficacy of its drug
candidates and gain approval of its drug candidates on a timely
basis, if at all; the preclinical and clinical results for
Blueprint Medicines' drug candidates, which may not support further
development of such drug candidates either as monotherapies or in
combination with other agents or may impact the anticipated timing
of data or regulatory submissions; the timing of the initiation of
clinical trials and trial cohorts at clinical trial sites and
patient enrollment rates; actions of regulatory agencies, which may
affect the initiation, timing and progress of clinical trials;
Blueprint Medicines' ability to obtain, maintain and enforce patent
and other intellectual property protection for AYVAKIT/AYVAKYT,
GAVRETO or any drug candidates it is developing; Blueprint
Medicines' ability to develop and commercialize companion
diagnostic tests for AYVAKIT/AYVAKYT, GAVRETO or any of its current
and future drug candidates; Blueprint Medicines' ability to
successfully expand its operations, research platform and portfolio
of therapeutic candidates, and the timing and costs thereof;
Blueprint Medicines' ability to realize the anticipated benefits of
its executive leadership transition plan; and the success of
Blueprint Medicines' current and future collaborations, financing
arrangements, partnerships or licensing arrangements. These and
other risks and uncertainties are described in greater detail in
the section entitled "Risk Factors" in Blueprint Medicines' filings
with the Securities and Exchange Commission (SEC), including
Blueprint Medicines' most recent Annual Report on Form 10-K, as
supplemented by its most recent Quarterly Report on Form 10-Q and
any other filings that Blueprint Medicines has made or may make
with the SEC in the future. Any forward-looking statements
contained in this report represent Blueprint Medicines' views only
as of the date hereof and should not be relied upon as representing
its views as of any subsequent date. Except as required by law,
Blueprint Medicines explicitly disclaims any obligation to update
any forward-looking statements.
Trademarks
Blueprint Medicines, AYVAKIT, AYVAKYT,
GAVRETO and associated logos are trademarks of Blueprint Medicines
Corporation.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-appoints-john-tsai-md-to-its-board-of-directors-301715456.html
SOURCE Blueprint Medicines Corporation